INR is the preferred test for monitoring patients on vitamin K antagonist (VKA) therapy. The current standard method for monitoring INR is laboratory testing. However, the LumiraDx INR Test is performed at the point of care, which provides several benefits over laboratory testing.
* Supratherapeutic INR > 4.0 test result could take 90-180 seconds
The Instrument and Test Strips are integrated with several quality control checks to ensure the Instrument and Test are functioning correctly for every test run.
The workflow process is comprised of a single fingerstick and direct application to the Test Strip, along with step-by-step guidance of the Instrument to report a patient result.
In the OPTIMAL clinical trial, the LumiraDx INR Test correlated strongly with the Instrumentation Laboratory ACL Elite laboratory reference method. The trial found that the LumiraDx INR Test provided rapid and reliable INR results at the point of care1.
The LumiraDx INR Test is also highly precise. The following results represent the mean paired rep %CV for both direct and transfer tube application collected across multiple sites.
|Sample||n||Mean INR||Mean % CV|
1. Tait RC, Hung A, Gardner RS. Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clin Appl Thromb Hemost. 2019.
Not all products are available in all countries and regions. Please check with your local LumiraDx sales representative or distributor for availability in specific markets. Not available in the USA.
Supporting healthier lives, for individuals, communities and wider society.
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.